Premed · Premed · Genetics
Lecture 28: Course Review
Genetics
Learning Objectives
By the end of this lecture, students will be able to:
- Synthesize the major themes of the course from Mendelian inheritance through genomic medicine
- Integrate concepts across molecular, chromosomal, and population-level genetics
- Apply genetic principles to clinical scenarios involving diagnosis, risk assessment, and treatment
- Connect fundamental genetic mechanisms (replication, transcription, translation, regulation) to disease phenotypes
- Evaluate the interplay between genetic technologies and their ethical, legal, and social implications
- Identify the key concepts, problem-solving strategies, and high-yield topics for the final examination
Lecture Content
I. Module 1 Review: Mendelian Genetics and Inheritance Patterns (Lectures 1-6)
Mendel's Laws: Law of Segregation: two alleles for each gene separate during gamete formation; each gamete carries one allele. Law of Independent Assortment: alleles of different genes on different chromosomes assort independently. Molecular basis: meiosis I — homolog separation (segregation) and random orientation at metaphase I (independent assortment) Extensions of Mendelian inheritance (Lecture 3): Incomplete dominance (blended heterozygote phenotype), codominance (both alleles expressed — ABO blood groups) Multiple alleles, pleiotropy, epistasis, gene-environment interactions. Penetrance (proportion of individuals with genotype who show phenotype) vs. expressivity (degree of phenotype expression) Linkage and genetic mapping (Lecture 4): Genes on the same chromosome tend to be inherited together (linked) Recombination frequency between loci reflects their distance (1% recombination = 1 centiMorgan) Three-point testcross to determine gene order and map distances. Chromosome structure and abnormalities (Lectures 5-6): Karyotyping, banding patterns, chromosome structure (centromere, telomere, p arm, q arm) Numerical abnormalities: aneuploidy (trisomy 21 — Down syndrome; monosomy X — Turner syndrome), polyploidy. Structural abnormalities: deletions, duplications, inversions, translocations (Robertsonian, reciprocal) Mechanisms: nondisjunction (meiosis I or II), unequal crossing over. Key problem-solving skills: Punnett squares, chi-square analysis, recombination mapping, pedigree interpretation.
II. Module 2 Review: Molecular Genetics (Lectures 7-11)
DNA structure and replication (Lecture 7): Watson-Crick double helix: antiparallel strands, complementary base pairing (A-T, G-C), major and minor grooves. Semiconservative replication (Meselson-Stahl experiment) Replication machinery: helicase, primase, DNA polymerase III (leading and lagging strand synthesis), ligase, topoisomerase, SSBPs. Leading strand (continuous) vs. lagging strand (Okazaki fragments) Telomere maintenance by telomerase. Mutations and DNA repair (Lectures 8-9): Point mutations: transitions, transversions; silent, missense, nonsense, frameshift. Trinucleotide repeat expansions (Huntington disease, Fragile X, myotonic dystrophy) DNA repair pathways: direct repair, base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), homologous recombination (HR), non-homologous end joining (NHEJ) Clinical consequences of repair defects: xeroderma pigmentosum (NER), Lynch syndrome (MMR), BRCA1/2 (HR) Transcription and RNA processing (Lecture 10): Prokaryotic transcription: RNA polymerase, sigma factor, promoter recognition (-10 and -35), termination (rho-dependent and rho-independent) Eukaryotic transcription: RNA Pol I (rRNA), Pol II (mRNA), Pol III (tRNA); general transcription factors (TFIID/TBP), TATA box; mRNA processing: 5' cap, 3' poly-A tail, splicing (intron removal by the spliceosome — snRNPs, U1, U2, U4, U5, U6) Alternative splicing: one gene → multiple mRNA isoforms → proteome diversity. Translation and genetic code (Lecture 11): Triplet code: 64 codons, 61 sense + 3 stop; degenerate (redundant) but unambiguous; tRNA structure, aminoacyl-tRNA synthetases (charging), wobble base pairing. Ribosome structure (small + large subunit), A site, P site, E site. Initiation (AUG, Met-tRNA, initiation factors), elongation (codon recognition, peptide bond, translocation by EF-G), termination (release factors at stop codons) Post-translational modifications: folding, cleavage, glycosylation, phosphorylation.
<image>Panel A: Integrated central dogma diagram — DNA replication (with key enzymes), transcription (with RNA processing steps: capping, splicing, polyadenylation), and translation (with ribosome, tRNA, and polypeptide chain); arrows connect each process, and the key enzymes/factors for each step are labeled. Panel B: Summary comparison table of mutation types — point mutations (silent, missense, nonsense, frameshift), chromosomal mutations (deletion, duplication, inversion, translocation), and dynamic mutations (trinucleotide repeats), with one clinical example for each type and the expected phenotypic consequence. Panel C: DNA repair pathway overview — a branching diagram showing the type of DNA damage (base modification, UV dimer, mismatch, single-strand break, double-strand break) and the corresponding repair pathway (BER, NER, MMR, HR, NHEJ), with the associated clinical syndrome when each pathway is defective.</image>
III. Module 3 Review: Gene Regulation and Epigenetics (Lectures 12-14)
Prokaryotic gene regulation (Lecture 12): Operon model: lac operon (inducible — negative control by LacI repressor + positive control by CAP-cAMP) trp operon (repressible — repressor activated by tryptophan; attenuation mechanism) Eukaryotic gene regulation (Lecture 13): Multiple levels: chromatin remodeling → transcriptional (enhancers, silencers, transcription factors) → post-transcriptional (alternative splicing, mRNA stability, miRNA) → translational → post-translational. Transcription factor domains: DNA-binding (zinc finger, helix-turn-helix, leucine zipper) and activation domains. Enhancers can act over long distances; mediator complex bridges enhancers and promoters. Epigenetics (Lecture 14): DNA methylation: CpG islands; methylation → gene silencing; maintained by DNMT1, established by DNMT3A/B. Histone modifications: acetylation (activation — HATs), deacetylation (silencing — HDACs), methylation (context-dependent) Chromatin remodeling complexes (SWI/SNF) Genomic imprinting: parent-of-origin-specific expression; Prader-Willi and Angelman syndromes. X-inactivation: XIST RNA, Barr body, random inactivation → mosaicism in females.
IV. Module 4 Review: Genetic Technologies (Lectures 15-18)
Recombinant DNA technology (Lecture 15): Restriction enzymes, DNA ligase, vectors (plasmids, BACs, YACs), transformation; cDNA libraries vs. genomic libraries. Southern blot (DNA), Northern blot (RNA), Western blot (protein) PCR, cloning, and sequencing (Lecture 16): PCR: denaturation, annealing, extension; exponential amplification; applications (diagnostics, forensics, cloning) RT-PCR and qPCR (quantitative real-time PCR) for gene expression analysis. Sanger sequencing: chain termination method with ddNTPs. Next-generation sequencing and genomics (Lecture 17): NGS platforms: massively parallel sequencing; WES, WGS, RNA-seq, ChIP-seq. Bioinformatics: read alignment, variant calling, annotation. Genomic databases: gnomAD, ClinVar, OMIM. CRISPR-Cas9 (Lecture 18): Mechanism: sgRNA guides Cas9 to target → DSB → NHEJ (knockout) or HDR (precise edit) Advanced tools: base editing, prime editing, CRISPRi/a, epigenome editing. Clinical applications: CASGEVY for sickle cell disease, in vivo editing for transthyretin amyloidosis.
V. Module 5 Review: Population, Quantitative, and Applied Genetics (Lectures 19-23)
Population genetics (Lecture 19): Hardy-Weinberg equilibrium: p + q = 1; p^2 + 2pq + q^2 = 1. Five assumptions: no mutation, no selection, infinite population, no migration, random mating. Clinical application: carrier frequency estimation (e.g., CF: q^2 = 1/2500 → 2pq ~ 1/25) Evolutionary forces: selection (directional, balancing), genetic drift (bottleneck, founder effect), mutation, migration, non-random mating. Quantitative genetics (Lecture 20): Polygenic inheritance: continuous variation, normal distribution. Heritability: H^2 = Vg/Vp (broad-sense); h^2 = Va/Vp (narrow-sense) GWAS: identify SNPs associated with complex traits; Manhattan plots; genome-wide significance (p < 5 x 10^-8) Polygenic risk scores: aggregate many small-effect variants into a single risk metric. Cancer genetics (Lecture 21): Oncogenes (gain-of-function, dominant): RAS, MYC, HER2, BCR-ABL. Tumor suppressors (loss-of-function, recessive at cell level): RB1, TP53, APC, BRCA1/2. Knudson's two-hit hypothesis; multi-step carcinogenesis (Vogelstein model for colorectal cancer) Precision oncology: targeted therapy matched to tumor mutations. Developmental genetics (Lecture 22): Maternal-effect genes → gap → pair-rule → segment polarity → homeotic (Hox) genes. Hox gene colinearity and conservation; signaling pathways (Wnt, Hedgehog, Notch, BMP) Mitochondrial inheritance (Lecture 23): mtDNA: 16,569 bp, 37 genes, maternal inheritance. Heteroplasmy and threshold effect; mitochondrial bottleneck. Major syndromes: MELAS, MERRF, LHON, Kearns-Sayre.
<image>Panel A: Hardy-Weinberg problem-solving framework — a step-by-step guide showing: (1) identify the given information (disease incidence or allele frequency), (2) determine q^2 or q, (3) calculate p, (4) calculate genotype and carrier frequencies, (5) apply to clinical scenario (e.g., couple's risk of having an affected child); a worked example for a specific autosomal recessive condition is included. Panel B: Cancer genetics integration diagram — a cell at the center with the key pathways to cancer radiating outward: oncogene activation (gain-of-function mutations in growth signaling), tumor suppressor inactivation (two-hit loss of cell cycle brakes), DNA repair deficiency (genomic instability accelerating mutation accumulation), and evasion of apoptosis; each pathway lists the key genes and associated hereditary syndromes. Panel C: Comparison of inheritance patterns summary chart — six columns for autosomal dominant, autosomal recessive, X-linked recessive, X-linked dominant, mitochondrial, and multifactorial inheritance; each column lists the key pedigree features, recurrence risks, and one clinical example.</image>
VI. Module 6 Review: Clinical and Applied Genetics (Lectures 24-27)
Genetic counseling and testing (Lecture 24): Pedigree construction and interpretation; Bayesian risk analysis. Types of tests: karyotype, FISH, CMA, gene panels, WES, WGS. Variant classification: ACMG 5-tier system (pathogenic → benign); VUS challenges. Prenatal testing (NIPT, CVS, amniocentesis), newborn screening, carrier screening, predictive testing. Pharmacogenomics (Lecture 25): CYP450 polymorphisms: CYP2D6 (codeine, tamoxifen), CYP2C19 (clopidogrel), CYP2C9/VKORC1 (warfarin) Metabolizer phenotypes: poor, intermediate, normal, ultra-rapid. HLA-drug associations: HLA-B57:01 and abacavir, HLA-B15:02 and carbamazepine. CPIC guidelines and clinical implementation. Ethics in genetics (Lecture 26): Four bioethical principles applied to genetics. GINA: protections and limitations. Germline vs. somatic gene editing ethics; He Jiankui case. DTC genetic testing, data privacy, duty to warn. Personalized medicine (Lecture 27): Diagnostic genomics for rare diseases (WES/WGS yield ~25-40%) Precision oncology (tumor profiling → targeted therapy) Gene therapy: in vivo (Luxturna, Zolgensma) and ex vivo (CASGEVY) RNA therapeutics: ASOs (nusinersen), siRNA (patisiran), mRNA vaccines. Barriers: cost, equity, education, data interpretation.
VII. High-Yield Integration Topics and Exam Strategies
Cross-cutting themes to understand deeply: The central dogma and how disruptions at each step cause disease. The relationship between genotype and phenotype — why it is rarely one-to-one. How the same gene can cause different diseases depending on the type and location of mutation. The balance between genetic and environmental contributions to phenotype. How genetic technologies (PCR, sequencing, CRISPR) are applied in both research and clinical settings. Problem-solving strategies: Pedigree analysis: first determine the inheritance pattern, then calculate risks. Hardy-Weinberg: always start by identifying what you know (usually q^2 from disease incidence) Molecular biology: trace the flow from DNA → RNA → protein and identify where a mutation disrupts the process. Gene regulation: consider the level of regulation (transcriptional, post-transcriptional, translational, post-translational) Common exam themes: Given a pedigree, determine inheritance pattern and calculate recurrence risk. Given a mutation, predict the effect on protein structure and function. Apply Hardy-Weinberg to calculate carrier frequencies. Interpret GWAS results (Manhattan plot, significance threshold) Match a hereditary cancer syndrome to its gene and recommended management. Explain why a genetic test result (including VUS) does or does not change clinical management. Evaluate the ethical dimensions of a genetics scenario.
<image>Panel A: Course concept map — a large interconnected diagram showing the major topics of the course organized by theme (Mendelian genetics, molecular genetics, gene regulation, genetic technologies, population genetics, clinical genetics) with arrows showing conceptual connections between them; for example, DNA repair connects to mutations, which connects to cancer genetics, which connects to precision oncology and genetic testing. Panel B: Exam preparation checklist — a structured list of the top 15 high-yield topics for the final exam, each with a brief one-line summary and the lecture number where it was covered; topics include Hardy-Weinberg calculations, pedigree analysis, mutation effects on protein, operon regulation, epigenetic mechanisms, CRISPR mechanism, cancer gene classification, mitochondrial inheritance features, pharmacogenomic metabolizer phenotypes, and ACMG variant classification. Panel C: Integration clinical vignette example — a brief patient scenario (e.g., a young woman with a family history of breast cancer) with arrows pointing to all the relevant course concepts that apply: BRCA1/2 tumor suppressor genes, Knudson two-hit hypothesis, genetic counseling principles, ACMG variant classification, targeted therapy (PARP inhibitors), ethical considerations of predictive testing, and carrier risk for offspring.</image>
